$0.94
(3.95%)
Add to watchlist
Create an alert
Stocks and Shares ISAUniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Information
About this company
Key people
Matthew Kapusta
Chief Executive Officer, Executive Director
Christian Klemt
Chief Financial Officer
Jeannette Potts
Chief Legal and Compliance Officer and Corporate Secretary
Walid Abi-Saab
Chief Medical Officer
Kylie Okeefe
Chief Customer and Strategy Officer
David Meek
Non-Executive Independent Chairman of the Board
Robert Gut
Non-Executive Director
Madhavan Balachandran
Non-Executive Independent Director
Rachelle Suzanne Jacques
Non-Executive Independent Director
Jack L. Kaye
Non-Executive Independent Director
Click to see more
Key facts
- Shares in issue62.29m
- EPICQURE
- ISINNL0010696654
- LocationNetherlands
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.43bn
- Employees209
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.